Molbio Diagnostics Ltd. launched an initial public offering today to raise approximately ₹940 crore [3] on Indian stock exchanges.
The move allows the company to scale its global manufacturing footprint and expand its diagnostic product portfolio, particularly its tuberculosis test kits. It also provides a mechanism for company promoters to monetize a portion of their holdings.
The subscription period for the offering runs from Aug. 10 to Aug. 12, 2024 [3]. The company has set a price band of Rs 768-807 per share [4], with a minimum subscription lot of 18 shares [5].
Of the total funds raised, ₹200 crore [1] is earmarked for capital expenditures. The remaining ₹740 crore [2] is designated for an offer-for-sale, which will reduce the overall stake held by the company's promoters.
Molbio Diagnostics currently operates six manufacturing sites worldwide [6] and serves customers in more than 90 nations [7]. The company is offering the IPO at a discount to the industry average price-to-earnings multiple of 64 [8].
The firm aims to utilize the fresh capital to strengthen its presence in the global healthcare market, specifically by enhancing its ability to produce and distribute diagnostic kits at scale.
“Molbio Diagnostics launched an initial public offering today to raise approximately ₹940 crore.”
This IPO signals Molbio Diagnostics' transition from a private entity to a public company to fuel aggressive growth in the infectious disease diagnostic sector. By balancing fresh capital for infrastructure with an offer-for-sale for promoters, the company is attempting to attract high-risk investors while maintaining a valuation that remains competitive against industry peers.
